The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called ...
ITP leads to abnormal bruising and bleeding thanks to low platelet levels—a type of blood cell that helps with clotting. A ...
Sept. 27, 2004 — Successful eradication of Helicobacter pylori infection results in significant platelet recovery in 56% of patients with chronic idiopathic thrombocytopenic purpura (ITP), according ...
Findings showed 23% of patients treated with rilzabrutinib achieved durable platelet response compared with none of the patients receiving placebo. The Food and Drug Administration (FDA) has approved ...
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that its collaboration partner, Kissei ...
EAST HANOVER, N.J., Oct. 18, 2017 /PRNewswire/ -- Novartis today announced long-term study results supporting the positive safety and efficacy of Promacta (eltrombopag) in adults with ...
Purpose: The pharmacology, pharmacokinetics, dosage and administration, efficacy, safety, effects on quality of life, and place in therapy of romiplostim are reviewed. Summary: Romiplostim is a second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback